Monthly Archives: May 2012

Pharmacists warn against counterfeit meds sold online

Posted: Published on May 31st, 2012

QUINCY, Ill. (WGEM) --A shortage of some prescription drugs or just the cost of medicine is driving more people to the Internet. They're counting on online pharmacies to deliver the pills they need. But you may not be getting what you paid for and it could be dangerous to your health. Dixie Wallace picked up her prescription from the Hy-Vee pharmacy. Wallacesays she's comfortable knowing exactly where it came from and would never buy her pills online. "The pharmacist checks everything and double checks. I would be very skeptical of that coming from India or wherever," said Wallace. Experts say Wallace is right to be skeptical. "Pretty much any name brand medication can have a counterfeit," said Hy-Vee pharmacist Jason Tipton. Pharmacists say some of the more popular counterfeit medications are Viagra and Adderall. Drug manufacturers now use holographic seals for consumers to know the difference between what is real and fake. FDA lab tests recently found counterfeit Adderall with the wrong active ingredient, containing pain medicine instead. But some counterfeits can contain more harmful substances. Read more: Pharmacists warn against counterfeit meds sold online … Continue reading →

Posted in Internet Pharmacy | Comments Off on Pharmacists warn against counterfeit meds sold online

DreamHost and StopBadware Combine Powers to Make the Web Safer

Posted: Published on May 31st, 2012

LOS ANGELES, CA--(Marketwire -05/31/12)- DreamHost, a global full-service web hosting company, has today announced a deep and meaningful partnership with nonprofit anti-malware organization StopBadware (www.stopbadware.org). DreamHost will contribute both funds and forensic intelligence to further StopBadware's tireless efforts to identify and help cleanse the Internet of websites distributing malware. DreamHost will also participate in, and supply color commentary to, Stop Badware's Partners Forum, an ongoing conversation among industry leaders and security experts. Members of the Partners Forum also meet on a monthly basis with the shared goal of making the Internet safer through a comprehensive combination of information sharing, group collaboration, and raw techie brainpower. Asked for comment about the arrangement, DreamHost customer Johnathan Doether offered, "I'm not the young man I used to be. I sometimes need some help in the bedroom department if you know what I mean." Pausing to deliver a creepy wink half-shrouded in unkempt gray eyebrow hair, Doether continued, "Imagine my surprise when I opened my own website one day only to discover that everything had been replaced by links to a Canadian pharmacy specializing in exactly what I was looking for. Classic glass half-full situation. All this happened because, well... I'm not exactly good … Continue reading →

Posted in Internet Pharmacy | Comments Off on DreamHost and StopBadware Combine Powers to Make the Web Safer

Heart-Attack-Patient-Receives-Adult-Stem-Cell-Therapy- – Video

Posted: Published on May 31st, 2012

30-05-2012 10:25 Excerpt from: Heart-Attack-Patient-Receives-Adult-Stem-Cell-Therapy- - Video … Continue reading →

Posted in Cell Therapy | Comments Off on Heart-Attack-Patient-Receives-Adult-Stem-Cell-Therapy- – Video

How to Use the Advanced Cell Therapy System – Video

Posted: Published on May 31st, 2012

30-05-2012 16:02 Ovation Cell Therapy Tips for Thicker, Stronger, Longer Hair. Original post: How to Use the Advanced Cell Therapy System - Video … Continue reading →

Posted in Cell Therapy | Comments Off on How to Use the Advanced Cell Therapy System – Video

First Success of Targeted Therapy in Most Common Genetic Subtype of Non-Small Cell Lung Cancer

Posted: Published on May 31st, 2012

ASCO Abstract 7503 Study reports first success of targeted therapy in most common genetic subtype of non-small cell lung cancer Newswise BOSTONA novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, an international clinical trial led by scientists at Dana-Farber Cancer Institute and other institutions will report at the annual meeting of the American Society of Clinical Oncology (ASCO) June 1-5 in Chicago. Pasi A. Jnne, MD, PhD, scientific co-director of Dana-Farbers Belfer Institute for Applied Cancer Science, will present the findings from the randomized phase II study (abstract 7503) on Monday, June 4, 3 p.m. CT, E Hall D2, McCormick Place. A video commentary by Jnne on the findings is available, youtu.be/eqTFj0Gu5Bw. The study involved 87 non-small cell lung cancer (NSCLC) patients whose tumors carry a mutation in the gene KRAS. Such tumors account for about 20 percent of NSCLC cases, but no targeted therapy has proved effective against them in previous clinical research. The drug under investigation, selumetinib, doesnt attack KRAS directly, but interferes with one of its molecular henchmen, a protein called MEK. Participants in the study all had advanced stages of the disease. They received … Continue reading →

Posted in Cell Therapy | Comments Off on First Success of Targeted Therapy in Most Common Genetic Subtype of Non-Small Cell Lung Cancer

NeoStem to Present at Six Conferences in June

Posted: Published on May 31st, 2012

NEW YORK, May 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company focused on cell based therapies, announced today that Company management will present at six conferences in June. International Society for Cellular Therapy Annual Meeting National Investment Banking Association Conference International Society for Stem Cell Research 10th Annual Meeting The Biotechnology Industry Organization (BIO) International Conference Alliance for Regenerative Medicine -- Clinical Outlooks for Regenerative Medicine 2012 Marcum's Inaugural MicroCap Conference About NeoStem, Inc. NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, LLC, also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and is enrolling patients … Continue reading →

Posted in Cell Therapy | Comments Off on NeoStem to Present at Six Conferences in June

Oral Transmucosal Drug Delivery

Posted: Published on May 31st, 2012

NEW YORK, May 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Oral Transmucosal Drug Delivery http://www.reportlinker.com/p0870772/Oral-Transmucosal-Drug-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. On the provider side, the development of alternative methods of drug administration has improved the ability of physicians to manage specific problems. Practitioners now recognize the rapid onset, relative reliability, and the general lack of patient discomfort when drugs are administered by the transmucosal route. We expect this market to experience healthy growth through 2015 as buccal technology is applied to existing drugs and as transmucosal formulations become an important route of administration for an increasing number of new NCEs. Growth in this sector will also be driven by the pressure to extend market protection for numerous existing drugs with soon-to-expire patents. Highlights Analyzes and evaluates oral transmucosal drug delivery technology platforms and their impact … Continue reading →

Posted in Drug Side Effects | Comments Off on Oral Transmucosal Drug Delivery

'Intelligent medicine' erases side effects

Posted: Published on May 31st, 2012

Public release date: 31-May-2012 [ | E-mail | Share ] Contact: Soeren Kragh Moestrup sm@biokemi.au.dk (45) 28-99-22-82 Aarhus University Scientists at Aarhus University, Denmark in collaboration with the biotech company Cytoguide now publish a key to use glucocorticoid steroids in a kind of intelligent medicine that specifically hits the relevant cells. Data are based on rodent studies but if this principle is translated to humans it may greatly improve todays hazardous treatment with this type of potent steroids. This is the main perspective in the research now published in the recognized research journal Molecular Therapy in the Nature Publishing group. 50-fold higher potency Synthetic glucocorticoid steroid are used in many acute and chronic inflammatory diseases including many autoimmune diseases such as rheumatoid arthritis. This is the most potent anti-inflammatory medicine, but its use is hampered by serious side effects such as osteoporosis, loss in muscle mass, diabetes and immunosuppression. The new data from the scientists now show that they can target the drugs directly to he 'macrophage' immune cells. These cells play a main role in inflammation and their damaging effect on the surrounding tissues is strongly dampened by the glucocorticoid steroids. The new technology is based on the coupling … Continue reading →

Posted in Drug Side Effects | Comments Off on 'Intelligent medicine' erases side effects

New drugs, fresh hope for autism patients

Posted: Published on May 31st, 2012

CHICAGO Lynn and Neil Balter always dreaded stage productions at their son Jack's elementary school. When Jack was up there with the other performers, the noise, the lights, the crowd almost always got to him, and he would "start spinning," wandering around the stage or turning in circles, Lynn says. "It usually turned into an embarrassing situation," she adds. But at a dance performance at Jack's Scottsdale, Arizona, school last December, something was different. "He was half a beat behind in the dance, but he did the whole thing," Neil says. "He participated and took the bow with his class." Afterward, Jack's teacher greeted the Balters in tears. "I don't know what is going on with this kid, but there is this miracle happening and I have a different kid at school," she told the Balters. Jack, 9 years old, has autism. What his teacher didn't know is that Jack was taking part in a clinical trial for a drug aimed at overcoming some of the social impairment associated with autism, a spectrum of disorders that range from the social awkwardness and narrow interests seen in Asperger syndrome to severe communication and intellectual disabilities. For years the best that doctors … Continue reading →

Posted in Drugs | Comments Off on New drugs, fresh hope for autism patients

Segal Announces New National Pharmacy Benefits Practice Leader

Posted: Published on May 31st, 2012

NEW YORK--(BUSINESS WIRE)-- Joseph A. LoCicero, President & CEO of The Segal Company has announced that Ritu Malhotra, PharmD, Vice President and Clinical Pharmacy Consultant, has been named National Pharmacy Benefits Practice Leader. Mr. LoCicero said, As National Pharmacy Benefit Practice Leader, Ritus role is to be a thought leader on prescription drug benefit plan design, cost savings strategies, clinical management strategies, practice development and market trends. Her experience in integrating clinical knowledge into managed care settings has been especially effective for our clients. We are looking forward to her leading our PBM technical team and the Rx consulting group. Dr. Malhotra will also support marketing and sales efforts and serve as the primary spokesperson on Rx- related matters. She will continue to work directly with clients on pharmacy benefit programs. Dr. Malhotra holds a Doctor of Pharmacy from the University of the Sciences, Philadelphia College of Pharmacy, and a BA in Biology from Lehigh University (Bethlehem, PA). She is an active member of the Academy of Managed Care Pharmacy (AMCP). Dr. Malhotra works out of the firms Chicago office and reports to Ed Kaplan, Senior Vice President and National Health Practice Leader. The Segal Company (www.segalco.com) is an independent, … Continue reading →

Posted in Pharmacy | Comments Off on Segal Announces New National Pharmacy Benefits Practice Leader